Scarica l'app Stockscreener
1.04
0.97%
0.01
Dopo l'orario di chiusura:
1.04
Precedente Chiudi:
$1.03
Aprire:
$1.06
Volume 24 ore:
7.91M
Relative Volume:
2.07
Capitalizzazione di mercato:
$227.48M
Reddito:
$95,000
Utile/perdita netta:
$-327.27M
Rapporto P/E:
-0.4906
EPS:
-2.12
Flusso di cassa netto:
$-239.25M
1 W Prestazione:
-1.89%
1M Prestazione:
-18.75%
6M Prestazione:
-26.24%
1 anno Prestazione:
-55.74%
Intervallo 1D:
$1.03
$1.08
Intervallo di 1 settimana:
$0.9842
$1.105
Portata 52W:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Nome
Allogene Therapeutics Inc
Settore
Industria
Telefono
(650) 457-2700
Indirizzo
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Confronta ALLO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.04 | 225.29M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Ripresa | Oppenheimer | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-05 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Iniziato | Citigroup | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-08-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-28 | Reiterato | B. Riley Securities | Buy |
| 2021-10-20 | Iniziato | Cowen | Outperform |
| 2021-10-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-10-08 | Downgrade | Stifel | Buy → Hold |
| 2021-09-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Ripresa | Jefferies | Buy |
| 2021-05-20 | Aggiornamento | Truist | Hold → Buy |
| 2021-05-14 | Iniziato | B. Riley Securities | Buy |
| 2021-01-26 | Aggiornamento | Stifel | Hold → Buy |
| 2020-12-10 | Ripresa | H.C. Wainwright | Buy |
| 2020-11-24 | Iniziato | BofA Securities | Buy |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-06-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-19 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-14 | Downgrade | SunTrust | Buy → Hold |
| 2020-04-13 | Iniziato | SunTrust | Buy |
| 2020-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-24 | Iniziato | Berenberg | Hold |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-11-04 | Iniziato | Canaccord Genuity | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-06-05 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Neutral |
| 2019-05-23 | Iniziato | Stifel | Hold |
| 2019-03-29 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie
ALPHA3 Trial Update: Contradictions in Enrollment, Data Expectations, and Lymphodepletion Strategies - AInvest
Transcript : Allogene Therapeutics, Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
Allogene's Strategic Milestone Progress in 2026 and Its Implications for CAR T Leadership - AInvest
Earnings call transcript: Allogene Therapeutics’ Q2 2025 earnings reveal strategic shifts - Investing.com Nigeria
Allogene Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Allogene Narrows Loss in Fiscal Q2 - Nasdaq
Allogene Therapeutics: Q2 Earnings Snapshot - San Francisco Chronicle
Allogene Therapeutics, Inc. SEC 10-Q Report - TradingView
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update - The Manila Times
Allogene's CAR T Trials Show Promise in Cancer and Autoimmune Disease, $302M Cash Position - Stock Titan
Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Will Allogene Therapeutics Inc. benefit from macro trendsMulti-Year Investment Performance Summary Report - Newser
Allogene Therapeutics Inc. stock trend forecastMarket Stability and Long-Term Growth Outlook - Newser
Volume spikes in Allogene Therapeutics Inc. stock – what they meanDaily Trade Monitor with Pattern Alerts - Newser
Can trapped investors hope for a rebound in Allogene Therapeutics Inc.Smart Trend Analysis With Buy Point Cues - Newser
Allogene Therapeutics shares rise 2.86% after-hours following Sumitomo Pharma's submission for Parkinson's disease treatment. - AInvest
Is Allogene Therapeutics Inc. meeting your algorithmic filter criteriaPre-Market Stock Movement Summary and Review - Newser
Follicular Lymphoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsights | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Bio - Barchart.com
Allogene Therapeutics Schedules Conference Call and Webcast to Discuss Q2 2025 Financial Results on August 13 - Quiver Quantitative
Allogene Therapeutics announces Q2 2025 financial results, conference call on August 13. - AInvest
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update - Stock Titan
How to integrate Allogene Therapeutics Inc. into portfolio analysis toolsFree Breakout Entry Signal Confirmation Tool - Newser
Allogene Therapeutics shares fall 1.36% intraday after Sumitomo Pharma and RACTHERA submit application for Parkinson's disease treatment. - AInvest
What makes Allogene Therapeutics Inc. stock price move sharplyEquity Signal Recap With Long-Term Summary - Newser
JMP Securities Reiterates Market Perform Rating for Allogene Therapeutics Inc. - AInvest
Allogene Therapeutics Maintains Buy Rating Amid Strategic Adjustments and Technological Advancements - AInvest
Patient Dies After Receiving Monoclonal Antibody Lymphodepletion Regimen in LBCL Trial for Allogene’s Cema-Cel - CGTLive®
Allogene Sticks With Standard Lymphodepletion In CAR-T Trial After Patient Death - insights.citeline.com
Allogene stock maintains Market Perform rating at Citizens JMP after trial adjustment - Investing.com Canada
Allogene stock continues ALPHA3 trial with standard FC regimen after safety event - Investing.com Canada
Allogene Scraps Immunosuppressive Antibody After Patient Death in Lymphoma Trial - BioSpace
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Benzinga
Patient death in Allogene trial - The Pharma Letter
What is Allogene Therapeutics Inc. company’s growth strategyBuild wealth steadily with proven investment strategies - Jammu Links News
What are the technical indicators suggesting about Allogene Therapeutics Inc.High-yield growth strategies - Jammu Links News
When is Allogene Therapeutics Inc. stock expected to show significant growthInvest confidently with market-leading analysis - Jammu Links News
How does Allogene Therapeutics Inc. compare to its industry peersMaximize your portfolio’s growth potential - Jammu Links News
Is it the right time to buy Allogene Therapeutics Inc. stockJaw-dropping returns - Jammu Links News
Is Allogene Therapeutics Inc. stock overvalued or undervaluedMaximize returns with disciplined investment techniques - Jammu Links News
What drives Allogene Therapeutics Inc. stock priceStrong return on assets - Jammu Links News
What are Allogene Therapeutics Inc. company’s key revenue driversUnstoppable profit momentum - Jammu Links News
How many analysts rate Allogene Therapeutics Inc. as a “Buy”Access daily stock market expert updates - Jammu Links News
What is the dividend policy of Allogene Therapeutics Inc. stockGet real-time alerts on high-potential stocks - Jammu Links News
What are the latest earnings results for Allogene Therapeutics Inc.Jaw-dropping returns - Jammu Links News
Allogene Therapeutics updates ALPHA3 trial protocol following safety event By Investing.com - Investing.com Australia
How volatile is Allogene Therapeutics Inc. stock compared to the marketBeginner Investor Report With Low Risk - Jammu Links News
Allogene Therapeutics Faces Market Volatility Amid Financial Challenges - StocksToTrade
Allogene Resets Clinical Course After Patient Death In Lymphoma StudyAllogene Therapeutics (NASDAQ:ALLO) - Benzinga
Regeneron cancer bispecific rejected again; Allogene discloses trial death - BioPharma Dive
Allogene Therapeutics updates ALPHA3 trial protocol following safety event - Investing.com
Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event - TipRanks
Allogene Therapeutics Inc Azioni (ALLO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):